CALC Quote, Financials, Valuation and Earnings

Agenus, Inc. has a net margin of -- compared to CalciMedica, Inc.'s net margin of -31.03%. CalciMedica, Inc.'s return on equity of -603.5% beat Agenus, Inc.'s return on equity of --.

CalciMedica, Inc. has a consensus price target of $10.33, signalling upside risk potential of 1666.38%. On the other hand Agenus, Inc. has an analysts' consensus of $15.50 which suggests that it could grow by 270.37%. Given that CalciMedica, Inc. has higher upside potential than Agenus, Inc., analysts believe CalciMedica, Inc. is more attractive than Agenus, Inc..

CalciMedica, Inc. has a beta of 0.726, which suggesting that the stock is 27.36% less volatile than S&P 500. In comparison Agenus, Inc. has a beta of 1.604, suggesting its more volatile than the S&P 500 by 60.406%.

CalciMedica, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Agenus, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CalciMedica, Inc. pays -- of its earnings as a dividend. Agenus, Inc. pays out -- of its earnings as a dividend.

CalciMedica, Inc. quarterly revenues are --, which are smaller than Agenus, Inc. quarterly revenues of $34.2M. CalciMedica, Inc.'s net income of -$10.8M is lower than Agenus, Inc.'s net income of -$10.6M. Notably, CalciMedica, Inc.'s price-to-earnings ratio is -- while Agenus, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CalciMedica, Inc. is -- versus 0.88x for Agenus, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Alnylam Pharmaceuticals, Inc. has a net margin of -- compared to CalciMedica, Inc.'s net margin of 16.99%. CalciMedica, Inc.'s return on equity of -603.5% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 107.73%.

CalciMedica, Inc. has a consensus price target of $10.33, signalling upside risk potential of 1666.38%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $449.32 which suggests that it could grow by 40.92%. Given that CalciMedica, Inc. has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe CalciMedica, Inc. is more attractive than Alnylam Pharmaceuticals, Inc..

CalciMedica, Inc. has a beta of 0.726, which suggesting that the stock is 27.36% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.387, suggesting its less volatile than the S&P 500 by 61.27%.

CalciMedica, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CalciMedica, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

CalciMedica, Inc. quarterly revenues are --, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.1B. CalciMedica, Inc.'s net income of -$10.8M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $186.4M. Notably, CalciMedica, Inc.'s price-to-earnings ratio is -- while Alnylam Pharmaceuticals, Inc.'s PE ratio is 141.27x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CalciMedica, Inc. is -- versus 11.46x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of -- compared to CalciMedica, Inc.'s net margin of 34.4%. CalciMedica, Inc.'s return on equity of -603.5% beat Eli Lilly & Co.'s return on equity of 104.39%.

CalciMedica, Inc. has a consensus price target of $10.33, signalling upside risk potential of 1666.38%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,209.21 which suggests that it could grow by 29.25%. Given that CalciMedica, Inc. has higher upside potential than Eli Lilly & Co., analysts believe CalciMedica, Inc. is more attractive than Eli Lilly & Co..

CalciMedica, Inc. has a beta of 0.726, which suggesting that the stock is 27.36% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.506, suggesting its less volatile than the S&P 500 by 49.45%.

CalciMedica, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.68% to investors and pays a quarterly dividend of $1.73 per share. CalciMedica, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 26.14% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

CalciMedica, Inc. quarterly revenues are --, which are smaller than Eli Lilly & Co. quarterly revenues of $19.3B. CalciMedica, Inc.'s net income of -$10.8M is lower than Eli Lilly & Co.'s net income of $6.6B. Notably, CalciMedica, Inc.'s price-to-earnings ratio is -- while Eli Lilly & Co.'s PE ratio is 40.61x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CalciMedica, Inc. is -- versus 12.82x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Molina Healthcare, Inc. has a net margin of -- compared to CalciMedica, Inc.'s net margin of -1.41%. CalciMedica, Inc.'s return on equity of -603.5% beat Molina Healthcare, Inc.'s return on equity of 10.89%.

CalciMedica, Inc. has a consensus price target of $10.33, signalling upside risk potential of 1666.38%. On the other hand Molina Healthcare, Inc. has an analysts' consensus of $150.65 which suggests that it could grow by 7.08%. Given that CalciMedica, Inc. has higher upside potential than Molina Healthcare, Inc., analysts believe CalciMedica, Inc. is more attractive than Molina Healthcare, Inc..

CalciMedica, Inc. has a beta of 0.726, which suggesting that the stock is 27.36% less volatile than S&P 500. In comparison Molina Healthcare, Inc. has a beta of 0.554, suggesting its less volatile than the S&P 500 by 44.602%.

CalciMedica, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Molina Healthcare, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CalciMedica, Inc. pays -- of its earnings as a dividend. Molina Healthcare, Inc. pays out -- of its earnings as a dividend.

CalciMedica, Inc. quarterly revenues are --, which are smaller than Molina Healthcare, Inc. quarterly revenues of $11.4B. CalciMedica, Inc.'s net income of -$10.8M is higher than Molina Healthcare, Inc.'s net income of -$160M. Notably, CalciMedica, Inc.'s price-to-earnings ratio is -- while Molina Healthcare, Inc.'s PE ratio is 16.72x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CalciMedica, Inc. is -- versus 0.17x for Molina Healthcare, Inc.. Usually stocks with elevated PS ratios are considered overvalued.